Paradoxical reaction to golimumab: Tumor necrosis factor inhibitor inducing psoriasis pustulosa

6Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

Abstract

Importance: Golimumab is a human monoclonal antibody, used for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Adverse reactions are increasing with this class of medication (tumor necrosis factor inhibitors). Observations: The authors present a case of a female patient who presented with psoriasis pustulosa after the use of golimumab for rheumatoid arthritis. Conclusions and Relevance: Paradoxically, in this case, golimumab, which is used for psoriasis, induced the pustular form of this disease. We are observing an increasing number of patients who develop collateral effects with tumor necrosis factor inhibitors, and the understanding of the mechanism of action and how these adverse reactions occur may contribute to avoid these sometimes severe situations. © 2013 S. Karger AG, Basel.

Cite

CITATION STYLE

APA

Lopes, M. S. S., Trope, B. M., Rodriguez, M. P. R. R., Grynszpan, R. L., Cuzzi, T., & Ramos-E-Silva, M. (2013). Paradoxical reaction to golimumab: Tumor necrosis factor inhibitor inducing psoriasis pustulosa. Case Reports in Dermatology, 5(3), 326–331. https://doi.org/10.1159/000350930

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free